Why the study?
Does rivaroxaban reduce the primary efficacy endpoint and death compared to vitamin K antagonists in atrial fibrillation patients with haemodynamically significant rheumatic heart disease?
Does rivaroxaban reduce the primary efficacy endpoint and death compared to vitamin K antagonists in atrial fibrillation patients with haemodynamically significant rheumatic heart disease?
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation and rheumatic heart disease, rivaroxaban is associated with a higher rate of death and primary efficacy endpoints compared to vitamin K antagonists.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2023) conducted an editorial in Brugada syndrome, atrial fibrillation, rheumatic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: